What Medical Device Teams Need From eConsent in CNS Studies
Direct answer
Medical device companies running CNS studies need eConsent that supports legally authorized representative signatures, clear workflows when a participant's decision-making capacity changes, and fast reconsent when a device protocol is amended. It should also produce a Part 11 compliant audit trail that holds up under an IDE inspection, whether consent happens in clinic or remotely.
Why is consent harder in CNS device studies?
CNS device studies, such as neurostimulation, neuromodulation, and neurodiagnostic device trials, often enroll people with conditions that can affect cognition, including dementia, Parkinson's disease, stroke, epilepsy, or depression. CNS studies, particularly in Alzheimer's and dementia, frequently involve patients with fluctuating cognitive capacity and requirements for legally authorized representative consent.
The ethical baseline is clear. All adults, including those with cognitive impairment, should be presumed able to consent unless there is a reasonable indication otherwise, and capacity should be judged by the individual's abilities rather than their diagnosis (MIT COUHES guidance on adults with cognitive impairment). NIH notes that impaired decision-making capacity need not prevent participation in research, but it does call for additional scrutiny and safeguards (NIH policy on questionable capacity to consent). For an eConsent platform, that translates into flexible signer roles and a documented process when capacity changes during a study.
What regulations apply to eConsent in device trials?
Most clinical evaluations of investigational devices need an approved Investigational Device Exemption (IDE), which allows the device to be used in a study to collect safety and effectiveness data (FDA overview of the IDE). FDA's electronic informed consent guidance, prepared jointly with OHRP and covering drugs, biologics, and devices, confirms that electronic consent must meet the same requirements as paper: 21 CFR Part 50 for informed consent, Part 56 for IRBs, and Part 11 for electronic records and signatures (FDA eConsent Q&A guidance).
Device studies add one more wrinkle: protocols and device software often change during the study. Every amendment that affects risk or procedures can trigger reconsent across all active participants, and each version needs to be tracked to the right person.
What should medical device companies look for in eConsent?
LAR and multi-signer support
Dedicated signature blocks for a legally authorized representative, plus optional witness or participant assent signatures.
Capacity change workflows
A clear, documented path to switch from participant consent to LAR consent (or back) if capacity changes mid-study.
Plain-language, multimedia content
Short videos, diagrams, and comprehension checks help people with cognitive impairment understand what an implant or procedure involves.
Version-controlled reconsent
Automated reconsent that pushes the new version to affected participants and logs who signed which version, and when.
Remote and hybrid consent
Many device participants have mobility limits, so remote consent with identity checks reduces travel for them and their caregivers.
Inspection-ready audit trail
Time-stamped, immutable records that connect consent to enrollment and device procedures.
Comparing eConsent platforms for medical device CNS studies
| Vendor | Known for | Fit for medical device and CNS studies |
|---|---|---|
| Curebase | Structured eConsent, eCOA/ePRO, and EDC on one data model | A strong fit for device companies that want LAR consent, reconsent tracking, and neurological outcomes in one connected record |
| Medidata Consent | Patient-facing eConsent integrated with Rave EDC, supporting onsite and remote consent | A fit for device companies already running on Rave EDC |
| Veeva SiteVault eConsent | Site-facing eConsent available at no cost to investigator sites | A fit when sites already use SiteVault, since it works regardless of the sponsor's EDC |
| Medrio eConsent | Electronic and paper consent with in-clinic, remote, and hybrid workflows and multi-signer support | A fit for early feasibility and pivotal device studies that mix consent modes |
| Medable Total Consent | Standalone eConsent for decentralized and hybrid trials with 120+ locales | A fit for multinational device programs with remote participants |
What should device companies ask eConsent vendors about CNS studies?
- How does the platform handle a switch from participant consent to LAR consent if capacity changes during the study?
- Can consent content include video, visuals, and comprehension checks written for people with cognitive impairment?
- How quickly can a new consent version be pushed to active participants after a device or protocol amendment, and how is each signature tied to its version?
- Does remote consent include identity verification that satisfies your IRB and FDA expectations?
- Can consent records link directly to enrollment and device procedure data for an IDE inspection?
Where does Curebase fit for medical device CNS studies?
Curebase's eConsent runs on the same data model as its eCOA/ePRO and EDC. For a device company studying a neurostimulation or neurodiagnostic product, that means consent status, LAR signatures, and reconsent history sit alongside cognitive assessments and device follow-up data. Study teams can see at a glance who has signed the current version before a procedure, which keeps enrollment moving and supports a clean inspection.
Frequently asked questions
Is electronic consent allowed in FDA-regulated medical device studies?
Yes. FDA and OHRP guidance on electronic informed consent covers drugs, biologics, and medical devices. Electronic consent must meet the same requirements as paper consent under 21 CFR Part 50, along with Part 56 and Part 11 for electronic records and signatures.
How does eConsent handle participants with cognitive impairment in CNS studies?
Good eConsent platforms support legally authorized representative signatures, optional assent from the participant, and plain-language multimedia content. They also document the process if a participant's decision-making capacity changes during the study.
Why is reconsent a bigger issue in device trials?
Device protocols and device software can change during a study, and amendments that affect risk or procedures often require participants to reconsent. eConsent with version control pushes the new form quickly and records exactly who signed which version.
Can CNS device participants consent remotely?
In many studies, yes, if the IRB approves the remote process and identity verification is in place. Remote consent can reduce travel for participants with mobility limits and for caregivers who act as legally authorized representatives.
What should medical device companies prioritize when choosing eConsent?
Priorities usually include LAR and multi-signer support, version-controlled reconsent, remote and hybrid consent options, and an audit trail that connects consent to enrollment and device procedures for IDE inspections.
Does Curebase offer eConsent for medical device CNS studies?
Yes. Curebase eConsent runs on one data model with its eCOA/ePRO and EDC, so LAR signatures, reconsent history, and neurological outcome data stay together in one connected record.
